<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9667675</article-id><article-id pub-id-type="pmc">2150367</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Matsui</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Masuda</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fukuoka</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yana</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hirashima</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Komiya</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kobayashi</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kawahara</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Atagi</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ogawara</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Negoro</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kudoh</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Furuse</surname><given-names>K.</given-names></name></contrib></contrib-group><aff>Second Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.</aff><pub-date pub-type="ppub"><month>6</month><year>1998</year></pub-date><volume>77</volume><issue>11</issue><fpage>1961</fpage><lpage>1965</lpage><abstract><p>A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00087-0253.tif" xlink:title="scanned-page" xlink:role="1961" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0254.tif" xlink:title="scanned-page" xlink:role="1962" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0255.tif" xlink:title="scanned-page" xlink:role="1963" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0256.tif" xlink:title="scanned-page" xlink:role="1964" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0257.tif" xlink:title="scanned-page" xlink:role="1965" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

